Oracle and AstraZeneca announced a non-binding agreement on Tuesday to explore how artificial intelligence and real-world patient data can accelerate identification of eligible clinical trial participants. The collaboration, disclosed in Oracle's corporate newsroom and an AstraZeneca release, targets one of drug research's biggest bottlenecks: costly, time-consuming patient recruitment.
The initial effort will focus on oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. The companies plan to use a continuous learning model that feeds insights from clinical trials and routine care into future study designs, safety monitoring and treatment decisions. They also intend to establish shared governance, reusable technical tools and common measures to assess results.
AstraZeneca CEO Pascal Soriot said pairing scientific expertise with Oracle's data and technology could help clinicians identify eligible patients earlier and improve trial design and execution. Oracle executive Mike Sicilia described healthcare as one of AI's most significant opportunities, while AstraZeneca's Anne-Claire Gerbaldi said connecting data across research, trials and routine care could improve safety monitoring and earlier diagnosis. Oracle Health and Life Sciences head Seema Verma noted patient-identification efforts would remain under the governance of health systems delivering care.
The agreement includes no public timeline, budget or binding targets, but successful pilots may be expanded to more diseases and countries.
Oracle shares rose 1.92% on Tuesday. Broader markets also recovered as oil prices fell: the Dow Jones added 1.06%, the S&P 500 rose 0.46% and the Nasdaq Composite gained 0.2%.
TD Cowen analyst Michael Elias wrote that Nvidia could be providing credit support to Oracle through financial backstops or by leasing computing capacity and subleasing it to Oracle. That could partly explain Oracle's recent data-centre leasing activity in Southeast Asia related to a reported Tencent agreement. A BNP Paribas survey indicated improving Oracle software demand in October, with Europe a bright spot and generative AI replacing cybersecurity as the highest-demand spending category.
